Radiolabeling of magnetic targeted carriers (MTC) with indium-111

Nuclear Medicine and Biology

Volumn 30, Issue 7, 2003, Pages 761-769

  Häfeli, Urs O ^a   Yu, Junfeng ^b   Farudi, Farhad ^a   Li, Yuhua ^c   Tapolsky, Gilles ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c FeRx Inc   (United States)

Author keywords

Imaging; Indium 111; Magnetic targeting; Microspheres; Radiolabeling; Yttrium 90

Indexed keywords

2,4 AMINOBENZOYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHELATING AGENT; INDIUM 111; ISOTOPE; SOLVENT; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHELATION; CHEMICAL PARAMETERS; CHEMICAL REACTION; CONTROLLED STUDY; DOSIMETRY; DRUG BINDING; DRUG STABILITY; FEMALE; ISOTOPE LABELING; MAGNETISM; NONHUMAN; PARTICULATE MATTER; PLASMA; QUANTITATIVE ANALYSIS; RADIOISOTOPE DISTRIBUTION; RAT; TECHNIQUE; TEMPERATURE; TIME;

EID: 0141783602     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00077-5     Document Type: Article

References (30)

1. Ercan M.T. Radioactive microparticles. Part 2: Medical applications. Arshady R. Microspheres, microcapsules and liposomes. Vol. 2. 1999;313-342 Citus Books, London.
2. Mayer L.D. Future developments in the selectivity of anticancer agents drug delivery and molecular target strategies . Cancer Metastasis Rev. 17:1998;211-218.
3. Dubowchik G.M., Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Therapeut. 83:1999;67-123.
4. Galanis E., Vile R., Russell S.J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol-Hematol. 38:2001;177-192.
5. Molema G. Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies. Pharm Res. 19:2002;1251-1258.
6. Luo Y., Prestwich G.D. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets. 2:2002;209-226.
7. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 43:2002;693-713.
8. Heppeler A., Froidevaux S., Eberle A.N., Maecke H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 7:2000;971-994.
9. Gordon L.I., Witzig T.E., Wiseman G.A., et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol. 29:2002;87-92.
10. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 27:2000;766-777.
11. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic Y-90 microspheres. J Nucl Med. 41:2000;1673-1681.
12. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 12:2001;1711-1720.
13. Arshady R. Microspheres, Microcapsules & Liposomes: Magneto- and Radiopharmaceuticals. 3 vol. 1st ed:2001;Citus Books, London.
14. Häfeli U.O. Chapter 18: Radiolabeled magnetic microcapsules for magnetically targeted radionuclide therapy. Arshady R. Microspheres, Microcapsules & Liposomes: Radiolabeled and magnetic particulates in medicine and biology. Vol. 3. 2001;559-584 Citus Books, London.
15. Rudge S.R., Kurtz T.L., Vessely C.R., Catterall L.G., Williamson D.L. Preparation, characterization, and performance of magnetic iron-carbon composite microparticles for chemotherapy. Biomat. 21:2000;1411-1420.
16. Valentini V., Balducci M., Tortoreto F., Morganti A.G., De Giorgi U., Fiorentini G. Intraoperative radiotherapy: current thinking. Eur J Surg Oncol. 28:2002;180-185.
17. Häfeli U., Pauer G., Failing S., Tapolsky G. Radiolabeling of magnetic particles with rhenium-188 for cancer therapy. J Mag Mag Mater. 225:2001;73-78.
18. Hayes R.L., Rafter J.J. Rhenium-188 as possible diagnostic agent. J Nucl Med. 7:1966;797.
19. 188Re Generator system for therapeutic applications. J Nucl Med. 28:1987;656-657.
20. Knapp F.F. Rhenium-188-A generator derived radioisotope for cancer therapy. Cancer Biother Radiopharm. 13:1998;337-349.
21. Clarke E.T., Martell A.E. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13, and 14-membered tetraazamacrocycles. Inorganica Chimica Acta. 190:1991;37-46.
22. 111Indium-DOTA chelates A simple and efficient method . Biocon Chem. 5:1994;101-104.
23. DeNardo S.J., Zhong G.R., Salako Q., Li M., DeNardo G.L., Meares C.F. Pharmacokinetics of chimeric L6 conjugated to Indium-111 and Yttrium-90-DOTA-peptide in tumor bearing mice. J Nucl Med. 36:1995;829-836.
24. Moi M.K., Meares C.F., DeNardo S.J. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of p-nitrobenzyl-DOTA and study of its yttrium(III) complex. J Am Chem Soc. 110:1988;6266-6267.
25. Allard M., Doucet D., Kien P., Bonnemain B., Caille J.M. Experimental study of DOTA-gadolinium. Pharmacokinetics and pharmacologic properties. Investigative Radiol. 23:(Suppl 1):1988;S271-274.
26. Bousquet J.C., Saini S., Stark D.D., et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiol. 166:1988;693-698.
27. n in mice. Int J Rad Appl Instrum Part B. Nucl Med Biol. 15:1988;395-402.
28. Burgess J. Man and the elements of groups 3 and 13. Chem Soc Rev. 1996;85-92.
29. Liu S., Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Biocon Chem. 12:2001;7-34.
30. ten Berge R.J., Natarajan A.T., Hardeman M.R., van Royen E.A., Schellekens P.T. Labeling with indium In-111 has detrimental effects on human lymphocytes. J Nucl Med. 24:1983;615-620.